Treatment priorities of people living with atopic dermatitis (AD)—or eczema— are at the core of a special initiative called “More Than Skin Deep.” AAFA has partnered with four nonprofit organizations to create a series of opportunities for your perspective to inform and shape development of drugs and medical devices designed to treat eczema.
A focal point of the initiative is a patient-focused drug development (PFDD) meeting to be held September 23, 2019 in the Washington, D.C. area. It will provide the eczema community an opportunity to speak directly to Food and Drug Administration (FDA) staff, representatives of pharmaceutical and medical device companies, and other key stakeholders. The PFDD series began in 2013 as a way for FDA and clinical trial sponsors to understand more fully the burdens of living with a particular medical condition, what patients most value in terms of treatment benefits, and what risks and side effects they are willing to tolerate.
The “More Than Skin Deep” initiative is the first of its kind for eczema and we encourage you to make it as powerful as possible by contributing your perspective. There are three ways for you to get involved! See more at www.MoreThanSkinDeep-Eczema.org:
We look forward to your involvement! Your voice and perspectives are essential for us to demonstrate that eczema is “more than skin deep.”